National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 11 of 2000)

Overview

The National Health Act 1953 was enacted to establish and maintain a national health scheme, providing for a range of health-related services and benefits, including the Pharmaceutical Benefits Scheme (PBS). The legislation was introduced to address the need for a coordinated and comprehensive approach to health services and medication benefits across Australia. Enacted by the Commonwealth Parliament, the Act aimed to ensure that Australians have access to necessary health services and medications, thereby improving overall public health outcomes. This particular legislative instrument, the Pharmaceutical Benefits Declaration under subsection 85(2AA), made by the Acting Assistant Secretary of the Pharmaceutical Benefits Branch, Department of Health and Aged Care, seeks to align the scope of the PBS by specifying which drugs and medicinal preparations are covered. The policy objective is to manage the inclusion and exclusion of pharmaceutical products on the PBS list efficiently, ensuring that the scheme remains effective and sustainable.

Scope and Application

The Pharmaceutical Benefits Declaration under subsection 85 (2AA) of the National Health Act 1953 applies specifically to the cessation of certain drugs and medicinal preparations from the Pharmaceutical Benefits Scheme (PBS). This legislative instrument affects the eligibility of specified medications for subsidies under the PBS, impacting both the suppliers and beneficiaries of these pharmaceutical products. The Declaration, which came into operation on 1 August 2000, removes the Diphtheria, Tetanus and Pertussis Vaccine - Adsorbed from the list of covered drugs and preparations under Part VII of the National Health Act 1953. This change pertains to the Commonwealth jurisdiction, thereby affecting entities and individuals within Australia who are involved in the distribution or consumption of this particular vaccine. Notably, the Declaration does not extend its application to other drugs or vaccines not listed in the Schedule, maintaining their status under the PBS. This legislative action is a direct application of the Act and does not extend or restrict its application through subordinate instruments.

Key Provisions

The key operative sections of the Declaration under subsection 85(2AA) of the National Health Act 1953, as exemplified in this legislative instrument, concern the cessation of certain drugs and medicinal preparations from being covered under Part VII of the Act (subsection 85(2AA)(2)). This means that the specified drug or medicinal preparation, in this instance, the Diphtheria, Tetanus, and Pertussis Vaccine - Adsorbed, will no longer be subject to the provisions outlined in Part VII of the National Health Act 1953. This change will take effect from 1 August 2000 as per subsection 85(2AA)(3), and is made by the Acting Assistant Secretary of the Pharmaceutical Benefits Branch, Department of Health and Aged Care, who acts as a delegate of the Minister for Health and Aged Care. The Act imposes obligations on the Pharmaceutical Benefits Advisory Committee to provide advice on whether certain drugs should remain covered under Part VII of the National Health Act 1953. In this case, the Acting Assistant Secretary obtained the necessary advice from the Pharmaceutical Benefits Advisory Committee before making the Declaration (subsection 85(2AB)). This ensures that decisions to delist drugs are informed and based on expert recommendations. Additionally, the Act mandates that the Acting Assistant Secretary, as a delegate, must formally declare the cessation of coverage for specified drugs, which is evidenced in the text of the Declaration. There are no explicit offences, penalties, or civil/criminal consequences mentioned in the text of this legislative instrument regarding the breach of the provisions outlined. The Declaration primarily serves to inform stakeholders that the Diphtheria, Tetanus, and Pertussis Vaccine - Adsorbed will no longer be covered under the Pharmaceutical Benefits Scheme from the specified date. The focus of the instrument is on the administrative process and the cessation of coverage rather than on punitive measures for non-compliance with these provisions.